S&P 500   4,231.41 (-1.33%)
DOW   33,047.10 (-1.16%)
QQQ   355.71 (-1.54%)
AAPL   172.25 (-0.86%)
MSFT   313.60 (-2.55%)
META   300.96 (-1.91%)
GOOGL   133.11 (-0.79%)
AMZN   125.45 (-3.10%)
TSLA   248.19 (-1.36%)
NVDA   438.48 (-2.09%)
NIO   8.73 (-0.68%)
BABA   84.69 (-2.13%)
AMD   100.76 (-2.43%)
T   14.66 (-0.07%)
F   12.09 (-1.79%)
MU   68.33 (+0.54%)
CGC   0.70 (-4.76%)
GE   107.81 (-0.90%)
DIS   80.09 (-1.93%)
AMC   8.10 (-0.61%)
PFE   34.03 (+0.27%)
PYPL   57.75 (-1.38%)
NFLX   378.26 (-0.54%)
S&P 500   4,231.41 (-1.33%)
DOW   33,047.10 (-1.16%)
QQQ   355.71 (-1.54%)
AAPL   172.25 (-0.86%)
MSFT   313.60 (-2.55%)
META   300.96 (-1.91%)
GOOGL   133.11 (-0.79%)
AMZN   125.45 (-3.10%)
TSLA   248.19 (-1.36%)
NVDA   438.48 (-2.09%)
NIO   8.73 (-0.68%)
BABA   84.69 (-2.13%)
AMD   100.76 (-2.43%)
T   14.66 (-0.07%)
F   12.09 (-1.79%)
MU   68.33 (+0.54%)
CGC   0.70 (-4.76%)
GE   107.81 (-0.90%)
DIS   80.09 (-1.93%)
AMC   8.10 (-0.61%)
PFE   34.03 (+0.27%)
PYPL   57.75 (-1.38%)
NFLX   378.26 (-0.54%)
S&P 500   4,231.41 (-1.33%)
DOW   33,047.10 (-1.16%)
QQQ   355.71 (-1.54%)
AAPL   172.25 (-0.86%)
MSFT   313.60 (-2.55%)
META   300.96 (-1.91%)
GOOGL   133.11 (-0.79%)
AMZN   125.45 (-3.10%)
TSLA   248.19 (-1.36%)
NVDA   438.48 (-2.09%)
NIO   8.73 (-0.68%)
BABA   84.69 (-2.13%)
AMD   100.76 (-2.43%)
T   14.66 (-0.07%)
F   12.09 (-1.79%)
MU   68.33 (+0.54%)
CGC   0.70 (-4.76%)
GE   107.81 (-0.90%)
DIS   80.09 (-1.93%)
AMC   8.10 (-0.61%)
PFE   34.03 (+0.27%)
PYPL   57.75 (-1.38%)
NFLX   378.26 (-0.54%)
S&P 500   4,231.41 (-1.33%)
DOW   33,047.10 (-1.16%)
QQQ   355.71 (-1.54%)
AAPL   172.25 (-0.86%)
MSFT   313.60 (-2.55%)
META   300.96 (-1.91%)
GOOGL   133.11 (-0.79%)
AMZN   125.45 (-3.10%)
TSLA   248.19 (-1.36%)
NVDA   438.48 (-2.09%)
NIO   8.73 (-0.68%)
BABA   84.69 (-2.13%)
AMD   100.76 (-2.43%)
T   14.66 (-0.07%)
F   12.09 (-1.79%)
MU   68.33 (+0.54%)
CGC   0.70 (-4.76%)
GE   107.81 (-0.90%)
DIS   80.09 (-1.93%)
AMC   8.10 (-0.61%)
PFE   34.03 (+0.27%)
PYPL   57.75 (-1.38%)
NFLX   378.26 (-0.54%)
NASDAQ:CERS

Cerus (CERS) Stock Forecast, Price & News

$1.51
-0.06 (-3.82%)
(As of 01:16 PM ET)
Compare
Today's Range
$1.49
$1.57
50-Day Range
$1.50
$3.07
52-Week Range
$1.45
$4.25
Volume
484,324 shs
Average Volume
1.35 million shs
Market Capitalization
$273.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.88

Cerus MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
225.0% Upside
$4.88 Price Target
Short Interest
Healthy
2.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.05mentions of Cerus in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$12,675 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.22) to ($0.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

417th out of 976 stocks

Surgical & Medical Instruments Industry

52nd out of 99 stocks


CERS stock logo

About Cerus (NASDAQ:CERS) Stock

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

CERS Price History

CERS Stock News Headlines

Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
Cerus: Q2 Earnings Snapshot
Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates
Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
Cerus Corporation Common Stock (CERS)
Cerus bags additional $8.7M contract amendment
BTIG Keeps Their Hold Rating on Cerus (CERS)
See More Headlines
Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Company Calendar

Last Earnings
8/02/2023
Today
10/03/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:CERS
CUSIP
15708510
Employees
665
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$4.88
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$3.75
Forecasted Upside/Downside
+225.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-42,780,000.00
Pretax Margin
-32.99%

Debt

Sales & Book Value

Annual Sales
$162.05 million
Book Value
$0.39 per share

Miscellaneous

Free Float
168,057,000
Market Cap
$271.20 million
Optionable
Optionable
Beta
1.13

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. William M. GreenmanMr. William M. Greenman (Age 56)
    Pres, CEO & Director
    Comp: $1.33M
  • Mr. Kevin D. Green (Age 51)
    VP of Fin. & CFO
    Comp: $748.49k
  • Mr. Vivek K. JayaramanMr. Vivek K. Jayaraman (Age 48)
    Chief Operating Officer
    Comp: $861.67k
  • Ms. Chrystal Jensen (Age 52)
    Chief Legal Officer & Gen. Counsel
    Comp: $692.16k
  • Dr. Richard J. Benjamin (Age 63)
    Chief Medical Officer
    Comp: $719.74k
  • Dr. Laurence M. CorashDr. Laurence M. Corash (Age 79)
    Co-Founder & Chief Scientific Officer
  • Ms. Lori L. Roll
    VP of Admin. & Corp. Sec.
  • Mr. Matthew M. Notarianni
    Sr. Director of Investor Relations
  • Lainie Corten
    VP of Global Marketing
  • Ms. Carol M. MooreMs. Carol M. Moore (Age 73)
    Sr. VP of Regulatory Affairs, Quality & Clinical













CERS Stock - Frequently Asked Questions

Should I buy or sell Cerus stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares.
View CERS analyst ratings
or view top-rated stocks.

What is Cerus' stock price forecast for 2023?

3 analysts have issued 1-year target prices for Cerus' stock. Their CERS share price forecasts range from $3.75 to $6.00. On average, they predict the company's stock price to reach $4.88 in the next year. This suggests a possible upside of 225.0% from the stock's current price.
View analysts price targets for CERS
or view top-rated stocks among Wall Street analysts.

How have CERS shares performed in 2023?

Cerus' stock was trading at $3.65 on January 1st, 2023. Since then, CERS stock has decreased by 58.9% and is now trading at $1.50.
View the best growth stocks for 2023 here
.

When is Cerus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CERS earnings forecast
.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) issued its earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The biotechnology company earned $38.85 million during the quarter, compared to the consensus estimate of $40.80 million. Cerus had a negative net margin of 33.24% and a negative trailing twelve-month return on equity of 80.35%.

What ETFs hold Cerus' stock?

ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ARK Innovation ETF (ARKK).

What guidance has Cerus issued on next quarter's earnings?

Cerus updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$165.00 million, compared to the consensus revenue estimate of $172.56 million.

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

How do I buy shares of Cerus?

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $1.50.

How much money does Cerus make?

Cerus (NASDAQ:CERS) has a market capitalization of $271.20 million and generates $162.05 million in revenue each year. The biotechnology company earns $-42,780,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does Cerus have?

The company employs 665 workers across the globe.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001.

This page (NASDAQ:CERS) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -